Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 5, 2007, Pages

  Schupp, Nicole ^a,c   Schmid, Ursula ^a   Rutkowski, Przemyslaw ^b   Lakner, Ursula ^a   Kanase, Nilesh ^a   Heidland, August ^a   Stopper, Helga ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Candesartan; Deoxyribonucleic acid damage; Kidney cells; N acetylcysteine; Oxidative stress

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ARTICLE; CHROMOSOME ABERRATION; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; FLOW CYTOMETRY; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; MICRONUCLEUS TEST; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR UPREGULATION; SWINE;

EID: 34247847692     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00458.2006     Document Type: Article

References (31)

1. Burlinson B, Tice RR, Speit G, Agurell E, Brendler-Schwaab SY, Collins AR, Escobar P, Honma M, Kumaravel TS, Nakajima M, Sasaki YF, Thybaud V, Uno Y, Vasquez M, Hartmann A. Fourth International Workgroup on Genotoxicity Testing: results of the in vivo comet assay workgroup. Mutat Res In press.
2. Carey RM, Siragy HM. Newly recognized components of the reninangiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24: 261-271, 2003.
3. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 343: 1305-1311, 2000.
4. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16: 293-299, 2005.
5. Fenech M. Cytokinesis-block micronucleus assay evolves into a "cytome" assay of chromosomal instability, mitotic dysfunction and cell death. Mutat Res 600: 58-66, 2006.
6. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92: 2462-2470, 2001.
7. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
8. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91: 21-27, 2000.
9. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 112: 479-486, 2002.
10. Hannken T, Schroeder R, Stahl RA, Wolf G. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 54: 1923-1933, 1998.
11. Imlay JA, Linn S. DNA damge and oxigen radical toxicity. Science 240: 1302-1309, 1988.
12. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 20: 239-253, 2006.
13. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12: 70-88, 2003.
14. Laragh JH, Lewis K. Dahl Memorial Lecture. The renin system and four lines of hypertension research nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, and plasma renin and heart attack. Hypertension 20: 267-279, 1992.
15. Li Z, Yang J, Huang H. Oxidative stress induces H2AX phosphorylation in human spermatozoa. FEBS Lett 580: 6161-6168, 2006.
16. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 43: 142-152, 2004.
17. MacKenzie SM, Fraser R, Connell JM, Davies E. Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production. J Renin Angiotensin Aldosterone Syst 3: 214-221, 2002.
18. Mazza F, Goodman A, Lombardo G, Vanella A, Abraham NG. Heme oxygenase-1 gene expression attenuates angiotensin II-mediated DNA damage in endothelial cells. Exp Biol Med (Maywood) 228: 576-583, 2003.
19. Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 23: 240-255, 2005.
20. Quan S, Yang L, Shnouda S, Schwartzman ML, Nasjletti A, Goodman AI, Abraham NG. Expression of human heme oxygenase-1 in the thick ascending limb attenuates angiotensin II-mediated increase in oxidative injury. Kidney Int 65: 1628-1639, 2004.
21. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386, 2000.
22. Schupp N, Schinzel R, Heidland A, Stopper H. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors. Ann NY Acad Sci 1043: 685-695, 2005.
23. Singh N, McCoy M, Tice R, Schneider E. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175: 184-191, 1988.
24. Siragy HM, Howell NL, Ragsdale NV, Carey RM. Renal interstitial fluid angiotensin. Modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension 25: 1021-1024, 1995.
25. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm 1: 3, 2004.
26. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10: 405-410, 2005.
27. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 5: 307-323, 2005.
28. Ullian ME, Gelasco AK, Fitzgibbon WR, Beck CN, Morinelli TA. N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells. J Am Soc Nephrol 16: 2346-2353, 2005.
29. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40, 2006.
30. Wang CT, Navar LG, Mitchell KD. Proximal tubular fluid angiotensin II levels in angiotensin II-induced hypertensive rats. J Hypertens 21: 353-360, 2003.
31. Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl 24: S15-S21, 2006.